Two ‐year persistence of golimumab as second‐line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real‐life data from the LORHEN registry

ConclusionsOur real‐life data confirmed switching to a second TNFi as a good option for treating first‐line TNFi failures in RA, especially in combination with sDMARDs. Second‐line golimumab showed an overall better 2‐year drug survival compared with adalimumab and etanercept.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2F1756-185X.13199

Source: APLAR Journal of Rheumatology - October 30, 2017 Category: Rheumatology Authors: Ennio G. Favalli, Luigi Sinigaglia, Andrea Becciolini, Vittorio Grosso, Roberto Gorla, Chiara Bazzani, Fabiola Atzeni, Pier C. Sarzi Puttini, Enrico Fusaro, Raffaele Pellerito, Roberto Caporali Tags: Original Article Source Type: research